201150-73-4

Usage

Uses

Used in Pharmaceutical Manufacturing:
5-AMINO-2-BOC-1,2,3,4-TETRAHYDROISOQUINOLINE is used as a key reactant in the synthesis of various pharmaceutical compounds. Its presence of the t-butoxycarbonyl group allows for the protection of amines during organic synthesis, facilitating the production of complex molecules with desired properties.
Used in Chemical Synthesis:
In the field of chemical synthesis, 5-AMINO-2-BOC-1,2,3,4-TETRAHYDROISOQUINOLINE is utilized as an intermediate or building block for the creation of a wide range of organic compounds. Its unique structure and the presence of the protective BOC group make it a valuable component in the synthesis of various target molecules.
Used in Research and Development:
5-AMINO-2-BOC-1,2,3,4-TETRAHYDROISOQUINOLINE is employed as a research compound in academic and industrial laboratories. Its unique properties and reactivity make it a valuable tool for exploring new synthetic pathways, developing novel chemical reactions, and understanding the fundamental principles of organic chemistry.

InChI:InChI=1/C14H20N2O2/c1-14(2,3)18-13(17)16-8-7-11-10(9-16)5-4-6-12(11)15/h4-6H,7-9,15H2,1-3H3

Upstream product

• 41959-45-9 5-nitro-1,2,3,4-tetrahydroisoquinoline 
• 607-32-9 5-nitroisoquinoline 
• 1125-60-6 isoquinolin-5-ylamine 
• 115955-90-3 1,2,3,4-tetrahydroisoquinolin-5-amine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1430561-59-3 (E)-4-(2-(3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)acryloyl)-5-(methoxycarbonylamino)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid 
• 201150-74-5 5-Chloro-2,4-dimethoxy-N-[2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-5-yl)benzamide 

Relevant academic research and scientific papers

Tyrosine Kinase Inhibitor And Uses Thereof

Disclosed is a compound of Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, or their stereoisomers, which can be used as tyrosine kinase inhibitor. Also disclosed is a method for preparing the compound, a pharmaceutical composition and a kit comprising the compound, and uses of the compound. The compound can be used as tyrosine kinase inhibitor, or can be used to reduce or inhibit activity of EGFR or mutant thereof, such as EGFR mutant comprising T790M mutation, in a cell, or to treat and/or prevent a disease associated with overactivity of EGFR, such as cancer.

TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION

The present invention provides compounds of the general formulas I-IX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The present invention further provides treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Evaluation of a series of anticonvulsant 1,2,3,4-tetrahydroisoquinolinyl-benzamides

SAR studies around a series of N-(tetrahydroisoquinolinyl)-2-methoxybenzamides, identified by high-throughput screening at the novel SB-204269 binding site, have provided compounds such as 13, 29-33 with high affinity and excellent anticonvulsant activity in animal models. Copyright (C) 2000 Elsevier Science Ltd.